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Background: Bisphosphonates have a widespread indication for osteoporosis and are also applied in cancer
patients with skeletal-related conditions. Bisphosphonate-associated osteonecrosis of the jaw (BRONJ) is a feared
side effect which is hard to treat and often affects patient´s quality of life in an extensive manner. Adalimumab
(Humira®), a fully human recombinant antibody specific for tumor necrosis factor- α, is approved for treatment in
patients with Inflammatory Bowel Disease like ulcerative colitis or Crohn’s disease.
Case presentation: In March 2013, a 36-year-old female presented with right-sided perimandibular swelling,
recurrent facial pain and exposed necrotic bone after previous extraction of tooth 47. She had the medical history
of Crohn’s disease for more than one decade with chronic active enterocolitis, fistula disease as well as previous oral
manifestation and was currently treated with Adalimumab since September 2008. Due to steroid-induced
osteoporosis, diagnosed in 2004, she received oral Bisphosphonates (Risedronate) from 2004 until 2007 followed by
two infusions of Zoledronic acid in 2008 and 2009.
Conclusion: This patient with a medical history of Crohn’s disease and gastrointestinal remission under
Adalimumab therapy presented with osteonecrosis of the jaw after suspended oral and intravenous
Bisphosphonate therapy implicating that the biologic therapy with an anti-TNF-α antibody might promote the
manifestation of osteonecrosis and compromise oral healing capacity.
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Bisphosphonates are primarily applied in patients with
skeletal complications associated with osteoporosis as
well as malignancy [1,2]. Bisphosphonate–associated osteo-
necrosis of the jaw (BRONJ), first described in 2003,
poses a serious complication in patients currently or pre-
viously treated with Bisphosphonates and is associated
with exposed bone in the maxillofacial region for at least 8
weeks without any radiotherapy of the jaw in the past
[3,4]. The occurrence of BRONJ not only depends on the
duration of the BP therapy but also varies between oral
and intravenous application with far more cases reported
after intravenous infusions with a cumulative incidence of
0,8%- 12% [5,6]. Although the pathomechanism is not yet* Correspondence: raimund.preidl@uk-erlangen.de
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reproduction in any medium, provided the orcompletely understood, there are local risk factors like
extraction of teeth, placement of dental implants, periapical
surgery or dental abscesses going along with an increased
incidence of osteonecrosis [7]. Beyond this, genetic and
drug- related factors influence the appearance of BRONJ
[8]. Clinically BRONJ presents as non-vital, exposed bone
that might go along with inflammatory reactions due to
secondary infection and therefore the gingival or mucosal
tissue is usually sensitive to palpation. This process can
aggravate to bone sequestration going along with acute
osteomyelitis resulting in spreading and increased mobility
of additional teeth [9]. Presumably, BRONJ is associated
with infection and therefore immune-modulating drugs, as
applied in patients with Crohn’s disease or rheumatoid
arthritis, might be an important risk factor in the develop-
ment of necrotic lesions in the jaw [10,11]. We already
know that not only Bisphosphonates but also Denosumab
or other biologicals are under suspicion to promote ortd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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knowledge there is currently no published case of BRONJ
in a patient with Crohn’s disease also affecting the oral
cavity and treated with Adalimumab.Case presentation
A 36-year-old female presented in March 2013 with right-
sided perimandibular swelling, cervical lymphadenopathy
on the right side, dysphagia and pain on the lower face. In
January 2013, tooth 47 was removed by the family dentist
followed by episodes of recurrent pain during the fol-
lowing two months. On clinical investigation exposed
bone surrounded by gingival inflammatory reaction was
observed in the region of former tooth 47 (Figure 1).
Panoramic radiograph revealed a persistent extraction
socket of 47 (Figure 2a).
Her medical history revealed Crohn’s disease diagnosed
in March 2000 affecting the colon, small intestine and
stomach as well as aphthous oral lesions in the vestibulum
in the years 2000 and 2001, fistula disease and extrain-
testinal manifestation with arthralgia. The patient was
treated with varying doses of steroids together with 5-
aminosalicylic (5-ASA) between 2000 and 2008 (Figure 3).
In 2004 steroid-induced osteoporosis was diagnosed and
associated with sintering fractures in the lower lumbar
spine. Since then Calcium 500 mg and Cholecalciferol
1000 I.E. with concomitant oral Risedronate (Actonel®)Figure 1 Intraoperative situation with exposed necrotic bone
lingual and crestal in the region of former tooth 47 (white arrow).
Inflammatory reaction within the necrotic region is also leading to local
sugillations and bleedings as mucosal integrity seems to be disturbed.
Crowned tooth 46 was removed within the operation.35 mg/week was applied until 2007 followed by two single
4 mg infusions of Zoledronic acid (Alcasta®) in 2008 and
2009. In September 2008, prednisolon and 5-ASA therapy
was replaced by Adalimumab (Humira®) 40 mg/ 2 weeks
for 3 years and later on monthly (cumulative dose
approximately 3,6 g) leading to a total gastrointestinal
remission regarding Crohn’s symptoms at the end of 2009
confirmed by endoscopy, histology and clinical disease
activity in 2012. Between 2008 and 2013 recurrent events
of psoriatic-like lesions, lupus-like erythrodermia and
conjunctivitis were observed and treated with topically
applied medication. She reported to be allergic to metals
(gold, silver, nickel) and had no family history of Crohn’s
disease.
In March 2013, the patient was treated after previous
MR-imaging revealed increased signalling in the jaw in
the area of teeth 44 until 48 and additionally confirmed
prominent lymph nodes on both sides of the submandibu-
lar region (Figure 4). Due to the fact that the mandibular
bone was already exposed more than 8 weeks with no
medical history of radiotherapy, BRONJ was diagnosed
according to the AAOMS guidelines [6]. Surgical treatment
consisted of osteotomy until healthy bone with bleeding
from the surfaces was visible. Biopsies of bone were sent
for pathological examination. Additionally, sharp edges of
bone that can potentially traumatise the surrounding were
removed. A mucoperiosteal flap was raised and primary
wound closure was carried out without tension on the
mucoperiosteal flap after incision of the periosteum
with resorbable suture material (Vicryl 5–0, Ethicon,
Norderstedt, Germany) [14]. Furthermore tooth 46 had
to be removed because the necrotic bone affected the
roots. Antibiotic therapy consisting of ampicillin/sulbactam
(Ampicillin + Sulbactam-ratiopharm®, Ratiopharm, Ulm,
Germany) 3 g/day and metronidazol (Metronidazol B.
Braun®, B. Braun, Meisingen, Germany) 1,5 g/day and was
administered intravenously for 8 days. Oral food intake
was not allowed for 10 days and antiseptic mouth rinses
(Hexetidin, 5-Amino-1,3-bis(2- ethylhexal) hexahydro-
5-methylpyrimidin, Pfizer Pharma GmbH, Karlsruhe,
Germany) was performed three times a day.
Histological examination showed a granulomatous in-
flammatory reaction with necrotic, avital bone and actino-
myces colonisation but no growth of mycobacteria or
fungus and no multinucleated giant cells. Humira® therapy
was stopped in March 2013 after consultation with the
department of gastroenterology and due to the patient’s
wish suffering from recurrent psoriatic-like lesions,
lupus- like erythrodermia and conjunctivitis. 10 days after
discharge the patient presented with adequate wound
healing and mild clinical symptoms. During removal of
the stitches bone got re-exposed again indicating a com-
promised mucosal healing. The patient was followed up
weekly and received a second operative intervention at the
Figure 2 Pre- and postoperative panoramic radiographs. Preoperative radiograph (a) is showing a persistent extraction socket and hypersclerosis
of the mandibular bone in the region 46/47 after extraction of 47 in January 2013. Postoperative panoramic radiograph (b) revealing a reduction of the
mandibular bone height after repeated osteotomy and adequate ossification of the former extraction sockets.
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situation (Figures 2b and 5).
Discussion
Aminobisphosphonates are well established in the therapy
of osteoporosis and metastatic cancer disease. Although
BRONJ is a serious adverse event especially after intraven-
ous administration, Aminobisphosphonates improve cancer
control and increase long-term survival. This case report
presents an extraordinary course of osteonecrosis of the
jaw after mainly oral Bisphosphonate therapy and applica-
tion of Adalimumab in a Crohn’s disease patient affecting
almost the whole gastrointestinal tract. Bisphosphonates
can cause gastrointestinal mucosal injuries and reduceFigure 3 Drug regime since Crohn’s disease was diagnosed in 2000.bone remodelling by predominantly inhibiting osteoclasts
via RANKL. Furthermore these drugs seem to have anti-
angiogenic effects contributing to impaired wound-healing
for example after tooth extraction [15,16].
Adalimumab, representing a fully humanised anti-TNF-α
antibody, is an established biologic agent in the treatment
of Crohn’s disease with proven clinical benefits [17].
Unfortunately there are already some reports about ser-
ious adverse effects like new-onset of multiple sclerosis,
psoriasiform lesions, lupus like syndrome and infectious
complications including sepsis in patients treated with
the agent [18,19].
Cases of osteonecrosis in extracranial bones like the
femur or the talus in patients with Inflammatory Bowel
Figure 4 Magnetic Resonance Imaging (MRI), t2 weighted,
showing increased signalling in the jaw within the region of
teeth 44 until 47 as well as in the ipsi- and contralateral lymph
nodes (left side with white arrow). Additionally, perimandibular
soft tissue swelling is detectable on the affected side.
Figure 5 Postoperative situation in October 2013 showing
recovery of the affected side after extraction of tooth 46 and
repeated osteotomy.
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been published [20,21]. Some even maintain that avascu-
lar osteonecrosis might be an extraintestinal manifest-
ation of Inflammatory Bowel Disease although in some
cases the interval between steroid treatment and avascu-
lar bone necrosis was quite extended [22,23]. However,
in this report we present the first case of osteonecrosis
in the jaw with the underlying history of Crohn’s disease
being currently treated with Adalimumab (Humira®)
which can be seen in a certain correlation to other cases
demonstrating patients with osteonecrosis of the jaw
and biological anti-TNF-α therapy with Infliximab [13].
The EXTEND trial revealed improved mucosal healing
of gastrointestinal tissue under anti-TNF-α therapy [24],
despite this it is still unclear whether anti-TNF-α treat-
ment affects the oral mucosa and/or interferes with
bone physiology, bone turnover, local immunity and
wound repair on the long run. Pathomechanistically one
could speculate at this stage that an inhibitory effect of
Adalimumab on bone turnover might be mediated by a
reduction of RANKL which could already be shown in
patients with rheumatoid arthritis and anti-TNF-α therapy
[25,26]. Interestingly osteonecrotic lesions in the jaw have
also been reported within treatment regimes including
Denosumab in cancer patients assuming that a blockade
of receptor activator of nuclear factor-kappa-B (RANK)
and receptor activator of nuclear factor-kappa-B- ligand
(RANKL) interaction affects monocytic migration as well
as osteoclast function comparable to Bisphosphonates
[27]. We already know that Adalimumab induces apop-
tosis of activated human monocytes [28]. While apoptosis
of disease-specific or reactive monocytes may be beneficial
in idiopathic Inflammatory Bowel Disease, apoptosis of
monocytes activated by infectious agents still present
within the oral cavity may worsen wound healing, mucosal
repair and bone repair of the jaw after necrosis. However,
it still has to be investigated how bone metabolism and
local infections surveillance in patients with Inflammatory
Bowel Disease is influenced in the long run and how
therapeutic strategies including biological substances lead
to avascular bone necrosis in the jaw. Especially when
considering already observed infectious complications due
to immunosuppression associated with Adalimumab ap-
plication it has to be investigated if osteonecrotic lesions
might also occur because of spreading ongoing infec-
tions and/or have to be seen within the context of a
certain innate immune dysfunction lacking defensin
expression [29,30].
Regarding this case, on-going oral Crohn’s disease might
be a confounder in terms of mucosal healing. Although
the patient had no gastrointestinal symptoms including
aphthous lesions in the oral cavity during Adalimumab-
therapy, general oral mucosal healing capacities might be
compromised.
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Patients with Inflammatory Bowel Disease and planned
treatment with biological drugs like Adalimumab and a
history of Bisphosphonate therapy should be also clinically
investigated by a dentist before prescription of biologicals.
Furthermore they should be monitored carefully with
regard to osteonecrotic lesions of the jaw especially after
dental procedures or within periodontal disease.
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